• EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring tool for psychiatric conditions.
  • Pooled analysis of three prospective observational studies demonstrated 90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016).
  • EMOCARE also achieved strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001) on consecutive-visit measurements.
  • The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool.

SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based "Depression Thermometer" that powers the Emobot app now being deployed across the Hope Therapeutics network of interventional psychiatry clinics.

The poster, titled "Continuous Multimodal Passive Monitoring of Depressive Symptoms via Smartphone — Clinical Validation of EMOCARE," was presented at 11:45 AM ET by Tanel Petelot, CEO and Co-founder of Emobot, and co-authored by NRx Chief Executive Officer Jonathan C. Javitt, M.D., M.P.H. The interim pooled analysis combined three prospective observational studies (EMC1, EMC2-FR, EMC2-BD) in adults with Major Depressive Disorder or Bipolar Disorder, comparing EMOCARE scores against clinician-rated MADRS and HAM-D₁₇ and self-reported PHQ-9 and GAD-7. EMOCARE achieved within-person concordance with clinician-rated MADRS of r = 0.895 (p = 0.016) and consecutive-visit sensitivity to symptom change against PHQ-9 of ρ = 0.834 (p < 0.001), with continuous scores generated across the full follow-up window and a threshold of at least seven valid days per 14-day window confirming signal robustness.